Bartosz Dobies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bartosz Dobies has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ari Pall Isberg
Studies&Me A/S Copenhagen Denmark
5 shared publications - Elias Freyr Gudmundsson
Icelandic Heart Association, Kopavogur, Iceland
5 shared publications - Saemundur Oddsson
Department of Life Sciences, Sidekick Health , Vallakor 4, Kopavogur 200
5 shared publications - Gudlaug Bjornsdottir
Icelandic Heart Association, Kopavogur, Iceland
4 shared publications - Gudlaug Erla Akerlie Magnusdottir
Clinical Office, Sidekick Health, Vallakor 4, Kopavogur, 200, Iceland
4 shared publications - Hildigunnur Ulfsdottir
Clinical Office, Sidekick Health, Vallakor 4, Kopavogur, 200, Iceland
4 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 26 (1)
Investigating the instability of variable selection in Lasso-penalized Cox proportional hazards models: a simulation study on low-dimensional real-world medical data
Background: This study examined the stability of Lasso-penalized Cox proportional hazards models in low-dimensional clinical data. While Lasso is a popular method for simultaneous variable selection and regularization, its performance is known to vary across cross-validation (CV) runs due to random fold assignments. We aim to quantify the effects of the number of folds, stratification procedures, and elastic net mixing parameters on variable selection consistency. Methods: We analyzed real-world data from the Berlin Initiative Study in older adults, focusing on a subcohort with measurements of a novel biomarker ( n = 930) and assessing two time-dependent outcomes: all-cause mortality ( n = 882) and a cardiovascular composite endpoint (CE, n = 638). We applied Lasso to identify prognostic variables among 20 medically preselected predictors. In simulation studies, we systematically varied the number of CV folds, implemented stratification by nonproportional covariates, and adjusted the elastic net’s mixing parameter. We evaluated model stability by examining variability in the number of selected predictors and predictive performance via the C-index. Results: In our datasets, the number of CV folds substantially influenced model size and selection stability across random seeds, with higher fold numbers generally yielding more consistent results (optimal: 10-fold for mortality, 15 for CE). Stratifying by covariates, which violated the proportional hazards assumption, enhanced stability in some cases. The elastic net did not consistently outperform Lasso in terms of stability or predictive accuracy; mixing parameters below 0.6 led to greater variability. Conclusions: The stability of Lasso-penalized Cox models is strongly affected by CV design. Higher fold numbers and appropriate stratification can improve stability, but at a computational cost. Elastic net offers no clear benefit in this setting. These findings highlight how routine modelling choices, including default cross-validation settings, may influence variable selection stability in low-dimensional clinical survival analyses.
- 24 October 2026
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 26 (1)
Open AccessInvestigating the instability of variable selection in Lasso-penalized Cox proportional hazards models: a simulation study on low-dimensional real-world medical data
Background: This study examined the stability of Lasso-penalized Cox proportional hazards models in low-dimensional clinical data. While Lasso is a popular method for simultaneous variable selection and regularization, its performance is known to vary across cross-validation (CV) runs due to random fold assignments. We aim to quantify the effects of the number of folds, stratification procedures, and elastic net mixing parameters on variable selection consistency. Methods: We analyzed real-world data from the Berlin Initiative Study in older adults, focusing on a subcohort with measurements of a novel biomarker ( n = 930) and assessing two time-dependent outcomes: all-cause mortality ( n = 882) and a cardiovascular composite endpoint (CE, n = 638). We applied Lasso to identify prognostic variables among 20 medically preselected predictors. In simulation studies, we systematically varied the number of CV folds, implemented stratification by nonproportional covariates, and adjusted the elastic net’s mixing parameter. We evaluated model stability by examining variability in the number of selected predictors and predictive performance via the C-index. Results: In our datasets, the number of CV folds substantially influenced model size and selection stability across random seeds, with higher fold numbers generally yielding more consistent results (optimal: 10-fold for mortality, 15 for CE). Stratifying by covariates, which violated the proportional hazards assumption, enhanced stability in some cases. The elastic net did not consistently outperform Lasso in terms of stability or predictive accuracy; mixing parameters below 0.6 led to greater variability. Conclusions: The stability of Lasso-penalized Cox models is strongly affected by CV design. Higher fold numbers and appropriate stratification can improve stability, but at a computational cost. Elastic net offers no clear benefit in this setting. These findings highlight how routine modelling choices, including default cross-validation settings, may influence variable selection stability in low-dimensional clinical survival analyses.
- Open Access
- 12 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (5)
A digital health program enhances walking capacity and health status in symptomatic peripheral artery disease
Aims: Intermittent claudication (IC) is the most common manifestation of peripheral artery disease (PAD), an atherosclerotic condition associated with high cardiovascular morbidity and mortality. Management targets cardiovascular risk reduction and limb function, but effective non-invasive treatments for limb symptoms remain limited. The aim of this prospective, multicentre randomized controlled trial was to evaluate whether a 12-week multimodal smartphone-based digital health programme improves walking capacity and symptoms in patients with IC. Methods and results: The IPAD trial compared standard care alone with standard care plus a 12-week digital health intervention focused on lifestyle modification and physical activity, incorporating behavioural change techniques and gamification. The primary observer-blinded endpoint was maximum walking distance (MWD) during a 6-min walk test (6MWT), contextualized against minimal clinically important difference thresholds. Secondary endpoints included pain-free 6MWT distance and health-related quality of life (HRQoL). Over 21 months, 155 patients were randomized 1:1. Mean (SD) age was 71.8 (7.6) years. Compared with controls, the intervention group showed greater improvement in MWD (+21.44 m; 95% confidence interval [CI] 6.00–36.87; P = 0.007), exceeding the predefined 12-m MCID at the group level, and in pain-free walking distance (+32.95 m; 95% CI 0.68–65.23; P = 0.045). The relative risk of achieving an individual 12-m MCID did not differ between groups (risk ratio [RR] 1.27; 95% CI 0.91–1.76; P = 0.162). Exploratory analysis using a 20.1-m MCID showed a higher proportion of patients achieving the MCID in the intervention group (RR 1.97; 95% CI 1.16–3.34; P = 0.012). HRQoL improved nominally, with a between-group benefit on the EuroQol-5 Dimensions visual analogue scale (+6.29 points; 95% CI 1.33–11.20; P = 0.013). Conclusion: The digital health programme resulted in a clinically meaningful improvement in walking capacity in PAD patients with IC.
- 12 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (5)
Open AccessA digital health program enhances walking capacity and health status in symptomatic peripheral artery disease
Aims: Intermittent claudication (IC) is the most common manifestation of peripheral artery disease (PAD), an atherosclerotic condition associated with high cardiovascular morbidity and mortality. Management targets cardiovascular risk reduction and limb function, but effective non-invasive treatments for limb symptoms remain limited. The aim of this prospective, multicentre randomized controlled trial was to evaluate whether a 12-week multimodal smartphone-based digital health programme improves walking capacity and symptoms in patients with IC. Methods and results: The IPAD trial compared standard care alone with standard care plus a 12-week digital health intervention focused on lifestyle modification and physical activity, incorporating behavioural change techniques and gamification. The primary observer-blinded endpoint was maximum walking distance (MWD) during a 6-min walk test (6MWT), contextualized against minimal clinically important difference thresholds. Secondary endpoints included pain-free 6MWT distance and health-related quality of life (HRQoL). Over 21 months, 155 patients were randomized 1:1. Mean (SD) age was 71.8 (7.6) years. Compared with controls, the intervention group showed greater improvement in MWD (+21.44 m; 95% confidence interval [CI] 6.00–36.87; P = 0.007), exceeding the predefined 12-m MCID at the group level, and in pain-free walking distance (+32.95 m; 95% CI 0.68–65.23; P = 0.045). The relative risk of achieving an individual 12-m MCID did not differ between groups (risk ratio [RR] 1.27; 95% CI 0.91–1.76; P = 0.162). Exploratory analysis using a 20.1-m MCID showed a higher proportion of patients achieving the MCID in the intervention group (RR 1.97; 95% CI 1.16–3.34; P = 0.012). HRQoL improved nominally, with a between-group benefit on the EuroQol-5 Dimensions visual analogue scale (+6.29 points; 95% CI 1.33–11.20; P = 0.013). Conclusion: The digital health programme resulted in a clinically meaningful improvement in walking capacity in PAD patients with IC.
- 27 October 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 98 (1) , 53-61
Nutritional status and dietary needs of patients before the initiation of treatment for gastrointestinal cancers
Introduction: Gastrointestinal cancers are among the most commonly diagnosed malignancies and are associated with poor prognosis. An accurate assessment of nutritional status prior to the initiation of cancer treatment significantly influences both treatment effectiveness and patient tolerance.Aim: To evaluate the nutritional status and dietary needs of patients with gastrointestinal cancers before the start of oncological therapy.Material and methods: A retrospective analysis was conducted on data from 361 patients diagnosed with gastric, pancreatic, or colorectal cancer, who received dietary consultations prior to the initiation of cancer therapy in outpatient clinics in the Lesser Poland (2022–2024). The evaluation included body mass index (BMI), the Nutritional Risk Screening scale (NRS 2002), selectively available biochemical parameters, and the dietary interventions recommended.Results: A high risk of malnutrition (NRS ≥ 3) was identified in 62% of patients, most commonly among those with pancreatic cancer (77%) and gastric cancer (72%). There was no evident dependence between BMI and the risk of malnutrition. High-calorie diets were recommended for the majority of high-risk patients (85%), often in combination with immunonutrition in cases of planned surgical treatment.Conclusions: The findings confirm the need for routine nutritional screening at the diagnostic stage and the implementation of personalized dietary interventions as part of oncological prehabilitation. Moreover, the results highlight the necessity for physicians to more frequently order biochemical tests, such as albumin, prealbumin, and transferrin, which are essential for a reliable assessment of nutritional status prior to cancer treatment. The absence of these data in many cases impedes early detection of malnutrition and the initiation of appropriate therapeutic measures.
- 27 October 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 98 (1) , 53-61
Nutritional status and dietary needs of patients before the initiation of treatment for gastrointestinal cancers
Introduction: Gastrointestinal cancers are among the most commonly diagnosed malignancies and are associated with poor prognosis. An accurate assessment of nutritional status prior to the initiation of cancer treatment significantly influences both treatment effectiveness and patient tolerance.Aim: To evaluate the nutritional status and dietary needs of patients with gastrointestinal cancers before the start of oncological therapy.Material and methods: A retrospective analysis was conducted on data from 361 patients diagnosed with gastric, pancreatic, or colorectal cancer, who received dietary consultations prior to the initiation of cancer therapy in outpatient clinics in the Lesser Poland (2022–2024). The evaluation included body mass index (BMI), the Nutritional Risk Screening scale (NRS 2002), selectively available biochemical parameters, and the dietary interventions recommended.Results: A high risk of malnutrition (NRS ≥ 3) was identified in 62% of patients, most commonly among those with pancreatic cancer (77%) and gastric cancer (72%). There was no evident dependence between BMI and the risk of malnutrition. High-calorie diets were recommended for the majority of high-risk patients (85%), often in combination with immunonutrition in cases of planned surgical treatment.Conclusions: The findings confirm the need for routine nutritional screening at the diagnostic stage and the implementation of personalized dietary interventions as part of oncological prehabilitation. Moreover, the results highlight the necessity for physicians to more frequently order biochemical tests, such as albumin, prealbumin, and transferrin, which are essential for a reliable assessment of nutritional status prior to cancer treatment. The absence of these data in many cases impedes early detection of malnutrition and the initiation of appropriate therapeutic measures.
- Open Access
- 10 June 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (4) , 749-762
Effect of a digital health intervention on outpatients with heart failure: a randomized, controlled trial
Aims: Heart failure (HF) is associated with high mortality and reduced quality of life (QoL). Interventions encouraging a healthy lifestyle and self-care can reduce morbidity and HF-related hospitalizations. We conducted a randomized controlled trial (RCT) to assess the impact of a digital health programme on QoL and clinical outcomes of patients. The programme included remote patient monitoring (RPM), self-care, HF education, and empowered positive lifestyle changes. Methods and results: Patients (n = 175) received standard-of-care (SoC) at a HF outpatient clinic (control, n = 89) or SoC plus a digital health programme (intervention, n = 86) for 6 months, followed by a 6-month maintenance period. Compliance with RPM was 93% at 6 months. No significant between-group difference was found in the primary endpoint (health-related QoL), except in an exploratory subgroup of New York Heart Association class III patients, where the intervention group had a significantly smaller QoL decline (P = 0.023). For secondary endpoints, the intervention group had significantly greater improvements in self-care at 6 months (P < 0.001) and 12 months (P = 0.003), and in disease-specific knowledge at 12 months (P = 0.001). Several exploratory endpoints favoured the intervention, with significant improvements in triglycerides (P = 0.012), HbA1c (P = 0.014), and fasting glucose (P = 0.010). The TG/HDL cholesterol ratio and TG/glucose index improved significantly at both 6 and 12 months in between-group comparisons. Conclusion: Although the digital programme did not improve health-related QoL, it led to benefits in other important outcomes such as self-care, disease-specific knowledge, and several key metabolic parameters.
- 10 June 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (4) , 749-762
Open AccessEffect of a digital health intervention on outpatients with heart failure: a randomized, controlled trial
Aims: Heart failure (HF) is associated with high mortality and reduced quality of life (QoL). Interventions encouraging a healthy lifestyle and self-care can reduce morbidity and HF-related hospitalizations. We conducted a randomized controlled trial (RCT) to assess the impact of a digital health programme on QoL and clinical outcomes of patients. The programme included remote patient monitoring (RPM), self-care, HF education, and empowered positive lifestyle changes. Methods and results: Patients (n = 175) received standard-of-care (SoC) at a HF outpatient clinic (control, n = 89) or SoC plus a digital health programme (intervention, n = 86) for 6 months, followed by a 6-month maintenance period. Compliance with RPM was 93% at 6 months. No significant between-group difference was found in the primary endpoint (health-related QoL), except in an exploratory subgroup of New York Heart Association class III patients, where the intervention group had a significantly smaller QoL decline (P = 0.023). For secondary endpoints, the intervention group had significantly greater improvements in self-care at 6 months (P < 0.001) and 12 months (P = 0.003), and in disease-specific knowledge at 12 months (P = 0.001). Several exploratory endpoints favoured the intervention, with significant improvements in triglycerides (P = 0.012), HbA1c (P = 0.014), and fasting glucose (P = 0.010). The TG/HDL cholesterol ratio and TG/glucose index improved significantly at both 6 and 12 months in between-group comparisons. Conclusion: Although the digital programme did not improve health-related QoL, it led to benefits in other important outcomes such as self-care, disease-specific knowledge, and several key metabolic parameters.
- Open Access
- 17 February 2025
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 9 (1) , e72074
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals with Non-Alcoholic Fatty Liver Disease: A Prospective Single-Arm Feasibility Study (Preprint)
Background: A 3-month digital health program for NAFLD previously showed feasibility in engagement, program retention and clinical outcomes. This study investigates whether improvements in cardiometabolic risk factors achieved during a 3-month active program were sustained over a subsequent 6-month follow-up period. Objective: To evaluate whether the clinical improvements achieved after 3 months program were maintained over the subsequent 6-month period. Methods: In a 9-month, single-arm study using the Sidekick app, individuals with NAFLD and BMI>30 or metabolic syndrome, or type 2 diabetes (T2D) were included. The initial 3 months focused on providing education about diet, physical activity, stress management, and sleep followed by 6 months without coaching. The measured outcomes encompassed demographics, body composition, liver fat and blood markers. Results: Of 38 participants enrolled, 28 (82%) completed the nine-month study measurements 63.0 years (IQR 53.5-71.0) , 57.1% female). At nine months, the mean weight loss was 4.0 kg (SD 5.0, P<.001) compared to baseline. Liver fat decreased by 2.5% (SD 4.5, P<.001), with an 18.4% relative reduction. Systolic blood pressure decreased by 8.3 mmHg (SD 13.4, P<.001) and diastolic by 1.0 mmHg (SD 2.4, P=.02). Waist circumference decreased by 4.7 cm (SD 7.1, P<.001) and median HbA1c decreased by 18.5 mmol/mol (P<.001). Conclusions: Sustained improvements in liver fat and metabolic markers suggest that Sidekick Health’s digital program is a promising strategy for managing NAFLD without requiring continuous coaching. Clinical Trial: Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382
- 17 February 2025
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 9 (1) , e72074
Open AccessLong-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals with Non-Alcoholic Fatty Liver Disease: A Prospective Single-Arm Feasibility Study (Preprint)
Background: A 3-month digital health program for NAFLD previously showed feasibility in engagement, program retention and clinical outcomes. This study investigates whether improvements in cardiometabolic risk factors achieved during a 3-month active program were sustained over a subsequent 6-month follow-up period. Objective: To evaluate whether the clinical improvements achieved after 3 months program were maintained over the subsequent 6-month period. Methods: In a 9-month, single-arm study using the Sidekick app, individuals with NAFLD and BMI>30 or metabolic syndrome, or type 2 diabetes (T2D) were included. The initial 3 months focused on providing education about diet, physical activity, stress management, and sleep followed by 6 months without coaching. The measured outcomes encompassed demographics, body composition, liver fat and blood markers. Results: Of 38 participants enrolled, 28 (82%) completed the nine-month study measurements 63.0 years (IQR 53.5-71.0) , 57.1% female). At nine months, the mean weight loss was 4.0 kg (SD 5.0, P<.001) compared to baseline. Liver fat decreased by 2.5% (SD 4.5, P<.001), with an 18.4% relative reduction. Systolic blood pressure decreased by 8.3 mmHg (SD 13.4, P<.001) and diastolic by 1.0 mmHg (SD 2.4, P=.02). Waist circumference decreased by 4.7 cm (SD 7.1, P<.001) and median HbA1c decreased by 18.5 mmol/mol (P<.001). Conclusions: Sustained improvements in liver fat and metabolic markers suggest that Sidekick Health’s digital program is a promising strategy for managing NAFLD without requiring continuous coaching. Clinical Trial: Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382
- Open Access
- 17 February 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals with Non-Alcoholic Fatty Liver Disease: A Prospective Single-Arm Feasibility Study (Preprint)
BACKGROUND A 3-month digital health program for NAFLD previously showed feasibility in engagement, program retention and clinical outcomes. This study investigates whether improvements in cardiometabolic risk factors achieved during a 3-month active program were sustained over a subsequent 6-month follow-up period. OBJECTIVE To evaluate whether the clinical improvements achieved after 3 months program were maintained over the subsequent 6-month period. METHODS In a 9-month, single-arm study using the Sidekick app, individuals with NAFLD and BMI>30 or metabolic syndrome, or type 2 diabetes (T2D) were included. The initial 3 months focused on providing education about diet, physical activity, stress management, and sleep followed by 6 months without coaching. The measured outcomes encompassed demographics, body composition, liver fat and blood markers. RESULTS Of 38 participants enrolled, 28 (82%) completed the nine-month study measurements 63.0 years (IQR 53.5-71.0) , 57.1% female). At nine months, the mean weight loss was 4.0 kg (SD 5.0, P<.001) compared to baseline. Liver fat decreased by 2.5% (SD 4.5, P<.001), with an 18.4% relative reduction. Systolic blood pressure decreased by 8.3 mmHg (SD 13.4, P<.001) and diastolic by 1.0 mmHg (SD 2.4, P=.02). Waist circumference decreased by 4.7 cm (SD 7.1, P<.001) and median HbA1c decreased by 18.5 mmol/mol (P<.001). CONCLUSIONS Sustained improvements in liver fat and metabolic markers suggest that Sidekick Health’s digital program is a promising strategy for managing NAFLD without requiring continuous coaching. CLINICALTRIAL Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382
- 17 February 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessLong-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals with Non-Alcoholic Fatty Liver Disease: A Prospective Single-Arm Feasibility Study (Preprint)
BACKGROUND A 3-month digital health program for NAFLD previously showed feasibility in engagement, program retention and clinical outcomes. This study investigates whether improvements in cardiometabolic risk factors achieved during a 3-month active program were sustained over a subsequent 6-month follow-up period. OBJECTIVE To evaluate whether the clinical improvements achieved after 3 months program were maintained over the subsequent 6-month period. METHODS In a 9-month, single-arm study using the Sidekick app, individuals with NAFLD and BMI>30 or metabolic syndrome, or type 2 diabetes (T2D) were included. The initial 3 months focused on providing education about diet, physical activity, stress management, and sleep followed by 6 months without coaching. The measured outcomes encompassed demographics, body composition, liver fat and blood markers. RESULTS Of 38 participants enrolled, 28 (82%) completed the nine-month study measurements 63.0 years (IQR 53.5-71.0) , 57.1% female). At nine months, the mean weight loss was 4.0 kg (SD 5.0, P<.001) compared to baseline. Liver fat decreased by 2.5% (SD 4.5, P<.001), with an 18.4% relative reduction. Systolic blood pressure decreased by 8.3 mmHg (SD 13.4, P<.001) and diastolic by 1.0 mmHg (SD 2.4, P=.02). Waist circumference decreased by 4.7 cm (SD 7.1, P<.001) and median HbA1c decreased by 18.5 mmol/mol (P<.001). CONCLUSIONS Sustained improvements in liver fat and metabolic markers suggest that Sidekick Health’s digital program is a promising strategy for managing NAFLD without requiring continuous coaching. CLINICALTRIAL Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382
- Open Access
- 15 February 2024
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 8, e52576
User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study
Background: Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes. Objective: This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life. Methods: We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks. Results: In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) µU/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR –0.7 to 3.8) mmol/mol for hemoglobin A1c (HbA1c) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction. Conclusions: The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD. Trial Registration: Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382
- 15 February 2024
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 8, e52576
Open AccessUser Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study
Background: Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes. Objective: This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life. Methods: We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks. Results: In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) µU/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR –0.7 to 3.8) mmol/mol for hemoglobin A1c (HbA1c) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction. Conclusions: The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD. Trial Registration: Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382
- Open Access
- 12 September 2023
- Published by JMIR Publications Inc. in JMIR Preprints
User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study (Preprint)
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes. OBJECTIVE This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life. METHODS We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks. RESULTS In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) µU/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR –0.7 to 3.8) mmol/mol for hemoglobin A1c (HbA1c) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction. CONCLUSIONS The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD. CLINICALTRIAL Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382
- 12 September 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUser Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study (Preprint)
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes. OBJECTIVE This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life. METHODS We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks. RESULTS In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) µU/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR –0.7 to 3.8) mmol/mol for hemoglobin A1c (HbA1c) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction. CONCLUSIONS The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD. CLINICALTRIAL Clinicaltrials.gov NCT05426382; https://clinicaltrials.gov/study/NCT05426382